ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements with these filters
Promoter group trust Hardik Desai Family Trust bought 5,412 Trident Texofab shares on BSE. Promoter stake rose from 6.95% to 6.99%.
Hardik Desai Family Trust, a Promoter Group entity, bought 5,412 shares of Trident Texofab in the open market. Post-transaction holding rose to 6.99% of total equity.
Trident Texofab Limited has issued the notice for its 18th Annual General Meeting, scheduled for September 30, 2026, alongside its Annual Report for FY 2025-26.
Trident Texofab Limited has appointed M/s. PAAA & Associates as the Cost Auditor for the company, effective September 7, 2026.
Trident Texofab's board approved the Board's Report, called the 18th AGM for September 30, 2026, and appointed a cost auditor and scrutinizer.
CRISIL Ratings has withdrawn the credit rating for Trident Texofab Ltd. This action follows a recent review of the company's financial and operational standing.
Trident Texofab Limited has voluntarily withdrawn its credit ratings from CRISIL for bank facilities totaling Rs. 20 Crore. The ratings were reaffirmed at CRISIL B/Stable before withdrawal.
Hardik Desai Family Trust, a promoter group entity, acquired 15,000 shares of Trident Texofab Limited. This open-market transaction increased the promoter's stake to 6.89%.
Hardik Desai Family Trust, part of the promoter group, acquired 39,158 shares of Trident Texofab Ltd via open market, increasing their stake by 0.26%.
Trident Texofab Limited has announced the resignation of Shah Kailash & Associates LLP as Statutory Auditor and the appointment of Prit Agrawal & Co as Internal Auditor.
Trident Texofab Limited announced the resignation of its statutory auditor, Shah Kailash & Associates LLP, effective August 10, 2026, due to increasing professional workload.
Trident Texofab Ltd reported revenue from operations of ₹26.1 Cr (-7.1% YoY) and net profit of ₹0.5 Cr (-50.0% YoY) for Q1 FY27.
Trident Texofab will hold a board meeting on August 10, 2026. The meeting will consider the company's standalone financial results for the quarter ended June 30, 2026.
Trident Texofab forfeited 9,11,479 unexercised warrants after the exercise deadline passed. Outstanding convertible warrants are now nil.
Trident Texofab's credit rating was downgraded by CRISIL to 'B/Stable' from 'B+/Stable'. The downgrade reflects liquidity pressure and stretched working capital, despite promoter experience.
Trident Texofab's Board approved forfeiture of 9.11 lakh lapsed warrants, forfeiting Rs.1.60 Crore. No equity capital change occurred as no shares were allotted.
Trident Texofab Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor noted no material non-compliances, indicating robust adherence to SEBI listing regulations.
Trident Texofab Ltd reported revenue from operations of ₹33.6 Cr (-12.0% YoY) and a net loss of ₹2 Cr for Q4 FY26.
Trident Texofab approved audited FY26 results with annual revenue of ₹118.02 Crore. The board meeting concluded successfully with an unmodified auditor's opinion on standalone financials.
Trident Texofab adjourned its board meeting to May 30, 2026, citing audit delays. The trading window remains closed for 48 hours following the eventual results release.
Trident Texofab scheduled a board meeting for May 28, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-announcement.
Trident Texofab Limited confirmed it is 'Not a Large Corporate' as of March 31, 2026, per SEBI's debt security framework. The company reported outstanding borrowings of ₹20.21 Crore and maintains a B+ credit rating from CRISIL LTD. This routine regulatory disclosure clarifies the company's borrowing classification for the financial year.
Trident Texofab Ltd clarified to BSE that recent share price movements are purely market-driven. The company confirmed all material information has been disclosed and no pending announcements exist that could impact the price.